| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 2 topline data readout example | Phase 2 | — | Subscribe to access the data. | Small Molecules | Dermatologic System | ||
Phase 2 topline data readout example | Phase 2 | — | Subscribe to access the data. | Small Molecules | Dermatologic System | ||
Phase 2 topline data readout example | Phase 2 | — | Subscribe to access the data. | Small Molecules | Dermatologic System |
Recent Updates
Recently added Catalysts
Turn Therapeutics Inc.$9.44
+0.63 (+7.15%)
D 31Pipeline Score Richly Valued Pharma · Clinical
Market Cap
152.81 M
EPS
-0.18
P/E Ratio
-
Value Trade
537.15 K
SEC Financials
Q1 2026Dilution Risk
R&D Expenses
109.43 K
Operating CF
-1.63 M
Total Assets
18.64 M
Total Liabilities
12.53 M
Equity
6.12 M
D/E Ratio
12,345
31.71 %
Week
55.45 %
1 Month
49.13 %
3 Month
89.3 %
6 Month
-79.24 %
5 Year
-79.24 %
All Time
Cash Data
Cash Position
11.01 M
Monthly Burn
544.00 K
Runway
18.2 mo
Burn Trend
SEC Filing
May 11, 2026
Overview
Volume
163.69 K
52 Week Range
2.57 - 26.50
% held by Insiders
63.78 %
% held by Institutions
1.73 %
Enterprise Value
147.60 M
Total Shares
29.80 M
Short %
0.32 %
Float Shares
11.92 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Turn Therapeutics Inc.
55Total events
6Upcoming
14Tier-1 (high impact)
2025 – 2029Coverage
Upcoming catalysts 6
Event history 49
Jul 7, 2026
▲Interim AnalysisGX-03Trial
Completion of comprehensive interim analysis of adaptive Phase 2 trial
atopic dermatitissource ↗
Jul 7, 2026
◆Oral PresentationGX-03Presentation
Webcast presenting comprehensive interim analysis and optimized Stage 2 design for GX-03 in atopic dermatitis
atopic dermatitissource ↗
Jul 7, 2026
Jul 6, 2026
◆Interim AnalysisGX-03Trial
Comprehensive interim analysis of Stage 1 data from adaptive Phase 2 trial of GX-03
atopic dermatitissource ↗
Jul 6, 2026
◆Oral PresentationGX-03Presentation
Webcast presenting comprehensive interim analysis and optimized Stage 2 design for GX-03
atopic dermatitissource ↗
Jun 4, 2026
Jun 4, 2026
◆Oral PresentationGX-03Presentation
Presentation of detailed findings at Jefferies Global Healthcare conference
moderate-to-severe atopic dermatitissource ↗
Jun 2026
◆Topline ReadoutGX-03Clinical Data
Topline results expected for Phase 2 trial of GX-03 in atopic dermatitis
moderate-to-severe atopic dermatitissource ↗
Jun 1, 2026
▲Interim AnalysisGX-03Trial
Interim analysis findings from Phase 2 trial of GX-03 in atopic dermatitis
moderate-to-severe atopic dermatitissource ↗
May 27, 2026
▲PublicationGX-03Presentation
Peer-reviewed publication in Journal of Dermatological Treatment highlighting GX-03 activity in IL-36 associated inflammatory model
IL-36 associated inflammatory conditionssource ↗
May 19, 2026
●Oral PresentationPresentation
Turn Therapeutics to present at Jefferies Global Healthcare Conference 2026
May 18, 2026
◆Management ChangeCorporate
Appointment of Dr. Stephen M. Hahn as Executive Clinical and Regulatory Lead
Drug Pipeline Intelligence
D31
Pipeline Score $15M
Pipeline ValueRichly Valued
Valuation Signal1
Drugs Scored0.1x
rNPV / MCap Top 37%
Micro Cap (rank 576 of 912)
Percentile RankTurn Therapeutics Inc. faces pipeline headwinds (31/100), with $171M risk-adjusted pipeline value, led by GX-03 in Covid19 (Phase 2).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| GX-03 Small molecule | Covid19 | Phase 2 | NCT04951349 | 21% | $171M | COMPLETED | 85 | - | - | May 30, 2021 | - | Jul 6, 2021 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
GX-03 | moderate-to-severe atopic dermatitis | Phase 2 | 2026-06-01 | EASI 50: 92.6%; EASI 75: 70.4%; EASI 90 (4 weeks): 44.4%; EASI 90 (8 weeks): 51.9%; vehicle EASI 50: 65.2%; vehicle EASI 90 (4 weeks): 30.4%; vehicle EASI 90 (8 weeks): 34.8% Read More | Turn Therapeutics Reports Interim Analysis Findings and Adaptive Optimization Strategy from Phase 2 GX-03 Trial in Moderate-to-Severe Atopic Dermatitis Read More | |
GX-03 | moderate-to-severe atopic dermatitis | Phase 2 | 2026-06-01 | EASI 50: 92.6%; EASI 75: 70.4%; EASI 90 (4 weeks): 44.4%; EASI 90 (8 weeks): 51.9%; vehicle EASI 50: 65.2%; vehicle EASI 90 (4 weeks): 30.4%; vehicle EASI 90 (8 weeks): 34.8% Read More | Turn Therapeutics Reports Interim Analysis Findings and Adaptive Optimization Strategy from Phase 2 GX-03 Trial in Moderate-to-Severe Atopic Dermatitis Read More | |
GX-03 | moderate-to-severe atopic dermatitis | Phase 2 | 2026-06-01 | EASI 50: 92.6%; EASI 75: 70.4%; EASI 90 (4 weeks): 44.4%; EASI 90 (8 weeks): 51.9%; vehicle EASI 50: 65.2%; vehicle EASI 90 (4 weeks): 30.4%; vehicle EASI 90 (8 weeks): 34.8% Read More | Turn Therapeutics Reports Interim Analysis Findings and Adaptive Optimization Strategy from Phase 2 GX-03 Trial in Moderate-to-Severe Atopic Dermatitis Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in TTRX
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
TTRX Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
TTRX▲ +26.3%on this news
Turn Therapeutics Announces Final Stage 2 Design and Data-Driven Expansion of GX-03 Phase 2 Program in Atopic Dermatitis
Turn Therapeutics has announced the final design for its Stage 2 program and a data-driven expansion of the GX-03 Phase 2 program targeting atopic dermatitis. The announcement indicates a strategic move to enhance the clinical development of their treatment. Further details on the specific data and design elements were not disclosed in the article.
Read more →TTRX▲ +26.3%on this newsshared move
Turn Therapeutics to Host Webcast Presenting Comprehensive Interim Analysis and Optimized Stage 2 Design for GX-03 in Atopic Dermatitis
Turn Therapeutics is set to host a webcast to present a comprehensive interim analysis and the optimized design for Stage 2 of their GX-03 treatment for atopic dermatitis. This event aims to provide insights into the ongoing development and efficacy of the treatment. Further details will be shared during the webcast.
Read more →TTRX▼ -6.2%on this news· ran to -17% by day 3
Jefferies Global Healthcare Conference June 2026 2 Disclaimer Except for historical information set forth herein, the matters set forth in this presentation contain forward - looking statement s within the meaning of the
Turn Therapeutics presented at the Jefferies Global Healthcare Conference, discussing the innovative PermaFusion delivery platform and its applications in drug development. The company is focusing on precision immunomodulation therapies for inflammatory diseases, particularly moderate to severe atopic dermatitis, with its lead candidate GX-03 currently in Phase 2 trials. The presentation emphasized the zero reported adverse events and the patent protections surrounding their unique therapy approach. Future expectations include interim results of the ongoing clinical trials to assess efficacy and safety.
Read more →TTRX▲ +21.7%on this newsshared move
Turn Therapeutics Reports Interim Analysis Findings and Adaptive Optimization Strategy from Phase 2 GX-03 Trial in Moderate-to-Severe Atopic Dermatitis
Turn Therapeutics has reported interim analysis findings from its Phase 2 GX-03 trial focused on moderate-to-severe atopic dermatitis. The company is implementing an adaptive optimization strategy based on these findings. Further details on the results and implications for the trial were not disclosed in the article.
Read more →TTRXTurn Therapeutics Announces Peer-Reviewed Publication in Journal of Dermatological Treatment Highlighting GX-03 Activity in IL-36 Associated Inflammatory Model
Turn Therapeutics has announced a peer-reviewed publication in the Journal of Dermatological Treatment. The publication highlights the activity of GX-03 in an IL-36 associated inflammatory model. This development may contribute to the understanding of treatments for inflammatory skin conditions.
Read more →TTRXTurn Therapeutics Announces Peer-Reviewed Publication in Journal of Dermatological Treatment Highlighting GX-03 Activity in IL-36 Associated Inflammatory Model Study demonstrates statistically signi
Turn Therapeutics, Inc. announced the publication of peer-reviewed research in the Journal of Dermatological Treatment, which evaluates its lead program, GX-03, in an IL-36-associated inflammatory model. The study demonstrates that GX-03 has a clear clinical effect in treating such conditions, marking a significant step in understanding localized therapies for skin diseases. The article is the first in a series of planned scientific publications aimed at further exploring GX-03's activity, with additional research underway. Currently, GX-03 is being evaluated in a Phase 2 randomized controlled trial, with topline results expected in mid-2026.
Read more →TTRX▼ -7.1%on this news
Turn Therapeutics to Present at Jefferies Global Healthcare Conference 2026
Turn Therapeutics is set to present at the Jefferies Global Healthcare Conference in 2026. The announcement highlights the company's participation in a significant industry event, which may provide opportunities for networking and showcasing their developments.
Read more →TTRX▼ -7.1%on this news
Turn Therapeutics to Present at Jefferies Global Healthcare Conference 2026 Westlake Village, Calif.
Turn Therapeutics Inc. (Nasdaq: TTRX) has announced that its CEO, Bradley Burnam, will present at the Jefferies Global Healthcare Conference in New York City. This event will showcase the company's developments in targeted therapies for inflammatory skin diseases, particularly their lead investigational therapy, GX-03, which is currently in a Phase 2 trial for treating moderate-to-severe atopic dermatitis. The presentation is scheduled for May 19, 2026, at 9:55 AM EDT, and a live webcast will be available on the company's website.
Read more →TTRX▲ +21%on this newsshared move
Turn Therapeutics Appoints Physician-Scientist and Former FDA Commissioner, Dr. Stephen M. Hahn, as Executive Clinical and Regulatory Lead
Turn Therapeutics has appointed Dr. Stephen M. Hahn as its Executive Clinical and Regulatory Lead. Dr. Hahn, a physician-scientist and former FDA Commissioner, is expected to leverage his expertise to guide the company's clinical and regulatory strategies. This strategic appointment aims to strengthen Turn Therapeutics' position in the biopharma sector.
Read more →TTRX▲ +21%on this newsshared move
Turn Therapeutics Appoints Physician-Scientist and Former FDA Commissioner, Dr. Stephen M. Hahn, as Executive Clinical and Regulatory Lead Dr. Hahn Brings Unparalleled Clinical and Regulatory Expert
Turn Therapeutics has appointed Dr. Stephen M. Hahn, former FDA Commissioner, as Executive Clinical and Regulatory Lead. Dr. Hahn will guide the clinical strategy for GX-03, an investigational therapy for moderate-to-severe atopic dermatitis currently in Phase 2 trials. He brings a wealth of experience in clinical medicine, regulatory science, and a personal commitment to addressing inflammatory skin diseases. The company aims for GX-03 to offer localized treatment with minimal systemic effects, targeting a significant unmet need in patient care.
Read more →TTRXTurn Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Updates
Turn Therapeutics has reported its financial results for the first quarter of 2026. The company also provided updates regarding its corporate activities. However, the article lacks specific details on financial performance or future plans.
Read more →TTRXTurn Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Updates Phase 2 Trial for GX-03 in Moderate-to-Severe Atopic Dermatitis (AD) on Track, Topline Results Expected
Turn Therapeutics has released its financial results for the first quarter of 2026, showcasing a net loss while highlighting significant corporate developments. The company secured $7 million as part of a larger $25 million growth capital funding from Avenue Capital Group. Their lead product, GX-03, is undergoing a Phase 2 trial for moderate-to-severe atopic dermatitis, with topline results expected in mid-2026, which could influence the company's future strategy. The Phase 2 trial remains on track with an upcoming interim analysis, highlighting the focus on advancing their clinical pipeline despite financial challenges.
Read more →TTRXTurn Therapeutics Reports Full Year 2025 Financial Results and Provides Corporate Updates
Turn Therapeutics Inc. reported its financial results for 2025 and provided updates on its clinical programs. The company is on track with its Phase 2 trial of GX-03 for moderate-to-severe atopic dermatitis, expecting topline results in mid-2026. Additionally, it secured up to $25 million in growth capital and strengthened its leadership team.
Read more →TTRXTurn Therapeutics Secures Up to $25 Million in Financing From Avenue Capital Group
Turn Therapeutics has secured financing of up to $25 million from Avenue Capital Group. This funding aims to support the company's ongoing projects and initiatives. The terms of the financing have not been disclosed in detail, but it marks a significant step for Turn Therapeutics in its financial strategy.
Read more →TTRX▼ -8.8%on this news
Turn Therapeutics Appoints Dr. Robert Redfield as Senior Advisor of Health Policy and Regulatory Affairs
Turn Therapeutics has appointed Dr. Robert Redfield as Senior Advisor for Health Policy and Regulatory Affairs. Dr. Redfield will guide the clinical development and regulatory strategy for the company's lead therapy, GX-03, which is currently in Phase 2 trials. His extensive experience in public health and regulatory affairs is expected to accelerate the therapy's development.
Read more →TTRXTurn Therapeutics to Present at Upcoming TD Cowen and Oppenheimer Healthcare Conferences
Turn Therapeutics Inc. will present at the TD Cowen and Oppenheimer Healthcare Conferences. CEO Brad Burnam will discuss the company's dermatology pipeline and the ongoing Phase 2 clinical trial of GX-03, aimed at treating moderate-to-severe atopic dermatitis. The presentations will be accessible via webcast, with replays available for 30 days.
Read more →TTRX▼ -8.4%on this news
Turn Therapeutics Announces Corporate and Pipeline Updates and 2026 Outlook Ahead of the 44 th Annual J.P. Morgan Healthcare Conference Phase 2 trial of GX-03 for moderate-severe atopic dermatitis on track to complete bo
Turn Therapeutics announced significant corporate and pipeline updates ahead of the 44th Annual J.P. Morgan Healthcare Conference. The company is focused on its Phase 2 trial of GX-03 for moderate-severe atopic dermatitis, with interim results expected in the first half of 2026. They also expanded their vaccine pipeline to include a thermostable intranasal influenza vaccine candidate. A strategic partnership with Medline is expected to generate revenue in 2026, further enhancing their market presence.
Read more →TTRXTurn Therapeutics Appoints Martin Dewhurst to its Board of Directors Mr. Dewhurst Brings Over 30 Years of Life Sciences and M&A Experience to the Board, Aligning with the Company's Strategic Long-Term Goals for Growth an
Turn Therapeutics has appointed Martin Dewhurst to its Board of Directors, bringing over 30 years of experience in life sciences and mergers and acquisitions. Dewhurst's expertise is expected to support the company's strategic priorities, including disciplined portfolio expansion and partnership development. This appointment is seen as pivotal for Turn Therapeutics as it seeks to accelerate growth and enhance long-term value.
Read more →TTRX▼ -7%on this news· ran to -32% by day 3
Turn Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Updates Successfully began trading on NASDAQ under ticker TTRX on
Turn Therapeutics, a clinical-stage biotechnology company, reported its financial results for the third quarter of 2025 as it officially began trading on NASDAQ under the ticker TTRX. The company announced a global supply, development, and license agreement with Medline, enhancing its operational capabilities. Despite these advancements, Turn Therapeutics reported a significant net loss of approximately $1.9 million for the quarter and rising operating expenses. The company is focusing on developing potential therapies for eczema and onychomycosis and anticipates data from its lead program in early 2026.
Read more →TTRX▲ +13.4%on this newsshared move
Turn Therapeutics CEO, Bradley Burnam, Speaks with Former Director of the Centers for Disease Control and Prevention Dr. Robert Redfield, M.D.
Turn Therapeutics CEO Brad Burnam discussed the importance of restoring public trust in science with Dr. Robert Redfield, former CDC Director. The conversation highlighted the need for fact-based communication from health authorities. The interview is available on major podcast platforms and aims to engage biotech executives and public health figures in this critical dialogue.
Read more →TTRXTurn Therapeutics’ GX-03 Technology Named as One of “Five Novel Mechanisms Reshaping Atopic Dermatitis Treatment” by Patient Care Online Magazine
Turn Therapeutics has been recognized by Patient Care Online Magazine for its GX-03 technology, which is noted as one of the top innovations in treating atopic dermatitis. The technology targets IL-36, a key player in the inflammatory response associated with eczema and psoriasis. The company aims to bring its products to market, with topline data expected in early 2026.
Read more →TTRX▼ -6.1%on this newsshared move
Turn Therapeutics' GX-03 Technology Named as One of "Five Novel Mechanisms Reshaping Atopic Dermatitis Treatment" by Patient Care Online Magazine Turn's Topical IL36/IL31 Inhibitor Named Alongside Other Phase 2 & 3 Candi
Turn Therapeutics has announced that its GX-03 technology has been recognized as one of the 'Five Novel Mechanisms Reshaping Atopic Dermatitis Treatment' by Patient Care Online Magazine. This recognition highlights the innovative aspects of the topical IL-36/IL-31 inhibitor, which may provide patients with an alternative to systemic therapies. The company anticipates releasing topline data from its lead program in severe eczema in early 2026, reflecting its commitment to advancing dermatologic therapies.
Read more →TTRXData as Currency for Pharma
The article discusses the increasing importance of data as a currency in the pharmaceutical industry. It highlights how investors prioritize data over revenue, as evidenced by significant acquisitions of companies based solely on their promising research data. The author argues that clean, validated data is the key to a company's value and success in the market.
Read more →TTRXTurn Therapeutics Appoints Veteran Capital Markets Executive Andrew Scott as Vice President of Corporate Communications Los Angeles, CA
Turn Therapeutics has appointed Andrew Scott as Vice President of Corporate Communications. In his new role, he will manage investor relations and capital markets strategy, instrumental as the company enters a new phase of growth. Scott's extensive experience in the life sciences sector is expected to bolster Turn's efforts in expanding partnerships and advancing its clinical development. The appointment comes alongside the company’s significant achievements, including FDA clearances and ongoing clinical programs.
Read more →TTRXTurn Therapeutics Enters Global Supply, Development, and License Agreement with Leading Medical-Surgical Product Manufacturer and Distributor Medline
Turn Therapeutics has entered a global supply, development, and license agreement with Medline, a leading medical-surgical product manufacturer. This partnership aims to leverage Turn's proprietary PermaFusion® delivery platform for product development and commercialization. The collaboration is expected to enhance Turn's market presence while allowing the company to focus on scientific innovation.
Read more →TTRXTurn Therapeutics Enters Global Supply, Development, and License Agreement with Leading Medical-Surgical Product Manufacturer and Distributor Medline Agreement combines Turn's PermaFusion delivery platform with Medline's
Turn Therapeutics has announced a global supply and development agreement with Medline, the leading provider of medical-surgical products. This partnership aims to utilize Turn's PermaFusion delivery platform to boost product opportunities in both professional and retail markets. The collaboration is set to accelerate Turn's market entry while allowing the company to focus on innovation and product development. Financial specifics and product details remain confidential, with future updates expected as initiatives progress.
Read more →TTRX▲ +18.4%on this news
Recording of Public Shareholder Session – October 22, 2025
Turn Therapeutics hosted a public shareholder session on October 22, 2025, led by CEO Bradley Burnam. The session included discussions on the company's developments and featured insights from Dr. Robert Redfield, a former CDC director. Additionally, Turn Therapeutics' GX-03 technology received recognition for its innovative approach to treating atopic dermatitis.
Read more →TTRX▼ -5.5%on this newsshared move
Turn Therapeutics Provides Shareholder Update Highlighting Continued Execution Across Clinical and Strategic Milestones
Turn Therapeutics provided a shareholder update detailing progress in its clinical programs and a flexible financing strategy following its direct listing. The company is advancing a Phase 2 trial for GX-03, a treatment for eczema, with topline results expected in 2026. Additionally, Turn is developing a thermostable intranasal vaccine, with studies set to begin in Q4 2025.
Read more →TTRX▼ -11.8%on this newsshared move
Turn Therapeutics Provides Shareholder Update Highlighting Continued Execution Across Clinical and Strategic Milestones Company to host shareholder webinar today
Turn Therapeutics provided a shareholder update on its continued progress in clinical trials and capital strategy. The company is advancing its phase 2 trial of GX-03 for eczema, with 25% of the sample size enrolled and no reported safety concerns. Additionally, Turn's direct listing allows for flexible financing through an $85 million GEM Global Yield agreement. The firm is also set to begin in-vivo studies for its thermostable intranasal vaccine initiative in Q4 2025.
Read more →TTRXTurn Therapeutics Launches Webinar Series for Ongoing Shareholder Engagement, First Session October 22, 2025
Turn Therapeutics has announced the launch of a webinar series aimed at enhancing shareholder engagement, with the first session scheduled for October 22, 2025. The initiative includes a Founder Blog by CEO Bradley Burnam, which will provide updates and insights about the company's growth and innovation. This effort reflects the company's commitment to maintaining an active dialogue with its community and stakeholders.
Read more →TTRX▲ +10.6%on this newsshared move
Turn Therapeutics Appoints Dr. Kent Kester to Board of Directors
Turn Therapeutics has appointed Dr. Kent Kester to its Board of Directors. Dr. Kester is a renowned infectious disease physician with extensive experience in clinical development and public health. His leadership is expected to enhance Turn's strategic direction as the company progresses with its late-stage clinical programs. The appointment comes at a crucial time for the company as it aims to address serious infectious and inflammatory diseases.
Read more →TTRXTurn Therapeutics Appoints Arthur Golden to Board of Directors
Turn Therapeutics has appointed Arthur Golden to its Board of Directors, bringing extensive experience in corporate governance and M&A. Golden's background includes over 40 years at Davis Polk & Wardwell LLP and significant roles in various sectors. His expertise is expected to strengthen Turn's strategic direction as it advances its clinical programs.
Read more →TTRXWatch Full Measure Cover Story Featuring Our Founder
Turn Therapeutics' founder, Bradley Burnam, was featured in a cover story on the program Full Measure, hosted by Sharyl Attkisson. The segment details the company's journey from humble beginnings to its presence on the Nasdaq. It emphasizes the mission to aid millions through innovative technology, stemming from a personal story. The coverage also includes a podcast episode, further extending its reach.
Read more →TTRX▼ -19%on this news· ran to -45% by day 3shared move
Turn Therapeutics Rings Nasdaq Closing Bell
Turn Therapeutics celebrated its first day of trading on Nasdaq by ringing the Closing Bell. Founder and CEO Bradley Burnam reflected on the company's journey from humble beginnings to a public trading entity. The event highlights the company's growth and success in the biopharma sector.
Read more →TTRX▼ -30%on this newsshared move
Turn Therapeutics ($TTRX) to Ring the Closing Bell at Nasdaq
Turn Therapeutics recently celebrated a milestone by ringing the closing bell at Nasdaq. The event highlighted the company's achievements and its innovative GX-03 technology, which has been recognized for its impact on atopic dermatitis treatment. CEO Bradley Burnam's engagement with healthcare leaders further underscores the company's growing influence in the biopharma sector.
Read more →TTRXTurn Therapeutics to Commence Trading Today on Nasdaq
Turn Therapeutics, a clinical-stage biotechnology firm, is set to begin trading on the Nasdaq Capital Market under the ticker TTRX on October 8, 2025. The SEC approved its registration statement on September 30, 2025. The company will celebrate this milestone with a Closing Bell Ceremony at Nasdaq's MarketSite in New York. Turn Therapeutics focuses on dermatology, wound care, and infectious disease therapies.
Read more →TTRXAnnouncement of Expected First Day of Trading on Nasdaq Global Market
Turn Therapeutics announced its common stock is expected to begin trading on the Nasdaq Global Market under the ticker 'TTRX' on October 8, 2025. The company is focused on developing dermatology, wound care, and anti-infective therapies, with several FDA clearances already obtained. However, the approval for its Nasdaq listing is still pending, and forward-looking statements indicate potential risks.
Read more →TTRXSecond Open Investor Session on 9/25/25
Turn Therapeutics is hosting its second Open Investor Session on September 25, 2025, at 12 p.m. Eastern. The session will be presented by CEO Bradley Burnam and is open to all without prior registration. Attendees can view the presentation online, promoting transparency and investor engagement.
Read more →TTRXRecording of September 17, 2025 Open Investor Session
Turn Therapeutics hosted an Open Investor Session on September 17, 2025, led by Founder & CEO Bradley Burnam. The session included discussions on the company's advancements and featured insights from Dr. Robert Redfield, a former CDC director. Additionally, Turn's GX-03 technology was recognized for its potential impact on atopic dermatitis treatment.
Read more →TTRXTurn Therapeutics to Host Open Investor Session in Connection with Expected Public Listing on Nasdaq
Turn Therapeutics, a clinical-stage biotechnology company, will host an Open Investor Session on September 17 in connection with its planned public listing on Nasdaq. The session will be live-streamed and aims to provide insights into the company's operations and growth strategy. Turn Therapeutics is known for its work in dermatology, wound care, and infectious disease.
Read more →TTRXAppointment of Odyssey Transfer and Trust Company as Transfer Agent for Turn Therapeutics
Turn Therapeutics has appointed Odyssey Transfer and Trust Company as its new transfer agent. This change aims to improve the management of shareholder accounts. Shareholders will receive an email with instructions on accessing their accounts and can reach out to Odyssey for any inquiries. The transition is expected to enhance communication and service.
Read more →TTRXTurn Therapeutics Intranasal Vaccine Candidate Demonstrates Extended Stability
Turn Therapeutics has announced significant stability data for its intranasal vaccine candidate, which shows 14 days of viability at room temperature and 28 days under refrigeration. This development could reduce the need for ultra-cold storage, facilitating vaccine distribution to remote areas. Further studies are planned to evaluate extended stability and immunogenicity.
Read more →TTRXTurn Therapeutics Begins Clinical Trial of First Topical IL-36/IL-31 Inhibitor for Eczema
Turn Therapeutics has launched a clinical trial for its topical GX-03 formulation aimed at treating moderate-to-severe eczema. The trial, which began patient dosing on July 11 in Dallas, will evaluate the formulation's efficacy against key eczema-related cytokines. With a target enrollment of 114 patients, results are anticipated by the end of 2025.
Read more →TTRXKevin O’Leary Livestream Recap + Replay
Kevin O'Leary, known as Mr. Wonderful, expressed strong enthusiasm for Turn Therapeutics during a recent livestream. He highlighted the company's potential to address significant market needs with innovative solutions. O'Leary envisions a global distribution strategy and is keen to engage further with the company beyond the initial discussion.
Read more →TTRXTurn Therapeutics Announces Vaccine Breakthrough: Validates 100% VSV Recovery from Petrolatum Carrier at 24 and 72 Hours
Turn Therapeutics has announced a significant breakthrough in vaccine technology by achieving 100% recovery of vesicular stomatitis virus (VSV) from an oil-based carrier at room temperature. This advancement could reduce the need for cold storage, simplifying vaccine distribution, especially in remote areas. The company plans to conduct further stability challenges and in-vivo studies to develop a human-use vaccine.
Read more →TTRXFinal Crowdfund Round Launched Ahead of Eczema Trial Enrollment + Engagement with Clear Street to Explore Public Markets
Turn Therapeutics has launched its final crowdfunding round ahead of a clinical trial for its non-steroidal eczema treatment. The trial aims to evaluate the efficacy of its proprietary formula over eight weeks, with topline data expected by the end of 2025. Additionally, the company is exploring public market options with Clear Street to support its late-stage trials.
Read more →TTRXResponse to Inquiries Regarding Share Transfers
The company has issued a response to shareholder inquiries regarding share transfers during a restricted communication period. It outlines when restrictions will be lifted, how to initiate trades, and where to access account statements. Shareholders are reminded to consult their brokers for specific trading plans and to direct inquiries to Odyssey.
Read more →TTRXPE & Banking Experts Join Business Advisory Board
Turn Therapeutics has announced the appointment of Jeffrey Bunder and Peter Gould to its business advisory board. These additions bring significant expertise in finance, investment, and banking, which will aid the company in its governance and development plans as it prepares for a public listing. Both members have extensive backgrounds in their respective fields, promising valuable insights and support for the company's future.
Read more →TTRXTurn Therapeutics Achieves Major Milestone Toward Improving Vaccine Access
Turn Therapeutics has achieved a significant milestone by maintaining a live vaccine's viability for 24 hours at room temperature using its innovative oil suspension technology. This advancement could facilitate easier storage and transport of vaccines globally, particularly in areas lacking refrigeration. The company is now exploring the implications for needle-free, intranasal vaccines and aims to conduct further studies to enhance vaccine stability.
Read more →TTRXTurn Therapeutics Secures $75 Million Investment Commitment Tied to Public Listing
Turn Therapeutics has announced a $75 million investment commitment from GEM Global Yield LLC, aimed at supporting its public listing and enhancing its capital flexibility. The funding will assist in advancing its IL-31/36 inhibitor for eczema and onychomycosis programs. The partnership also allows for exploration in other areas like thermostable vaccine delivery. Turn Therapeutics has previously secured multiple FDA clearances and aims for new drug approvals.
Read more →TTRXNew Business Advisory Board
Turn Therapeutics has established a Business Advisory Board to provide strategic guidance during its rapid growth phase. This board includes three experienced members: Martin Dewhurst, Martin Bott, and Dr. Kent Kester, who have significant backgrounds in the pharmaceutical industry. Their expertise will assist the company in navigating business challenges and opportunities.
Read more →TTRXAtopic Dermatitis Drug Candidate Significantly Inhibits Key Cytokines in Expansion Study
Turn Therapeutics announced positive results for its atopic dermatitis drug candidate, GX-03, which significantly inhibited key cytokines in a biomarker study. The study demonstrated a notable reduction in the ISGA score, indicating effective treatment potential. The company plans to initiate phase 1b/2 efficacy trials in 2025, highlighting the drug's promising profile.
Read more →TTRXWhy Are Pharma Giants Buying So Many Assets Now?
Pharma companies are increasingly focusing on specific therapeutic areas, leading to a consolidation that poses significant revenue risks. With $180 billion at risk due to patent expirations, companies are compelled to acquire new assets. The atopic dermatitis market is expected to grow substantially, providing a potential avenue for investment and development.
Read more →TTRXAtopic Dermatitis Candidate Reduces Disease Severity by 57% In-Vivo
Turn Therapeutics' atopic dermatitis candidate demonstrated a significant 57% reduction in disease severity in an in-vivo model compared to placebo. The treatment showed a mean ISGA score of 1.44 after seven days, indicating notable improvement. The candidate is noted for its safe history in humans and lack of cytotoxicity, addressing a critical need for effective non-steroid treatments.
Read more →TTRXHow do doctors and researchers measure eczema?
The article discusses the Investigator's Static Global Assessment (ISGA) scale, which measures the severity of eczema from 0 to 4. A score of 0 indicates clear skin, while a score of 4 represents severe eczema. Effective treatments aim to reduce scores by at least 2 points, ideally achieving a score of 0-1. The evaluation period varies depending on the treatment type.
Read more →TTRXYou are waterproof
The article discusses the structure of skin and nails, emphasizing their protective qualities. It highlights the challenges of treating toenail fungus with current medications and introduces a new technology that effectively penetrates infected nails. The company is pursuing FDA approval for its innovative treatment, aiming to improve the quality of life for millions affected by this condition.
Read more →TTRXIt’s a microbial world…we’re just living in it
The article emphasizes the importance of microbes in our lives, highlighting their role in health and digestion. It discusses the balance between harmful and beneficial microbes, advocating for a respectful understanding of these organisms. The author also mentions the non-cytotoxic nature of their drug candidate PHMB, which is approved by the FDA.
Read more →TTRXThe ‘why’ behind eczema
The article discusses the Hexagen formula's efficacy in treating moderate to severe eczema, emphasizing the importance of understanding its mechanism. Research from Johns Hopkins reveals that eczema is linked to excess staph aureus bacteria, which triggers inflammation. The author advocates for proactive treatment to prevent inflammation, highlighting their product's non-sensitizing antimicrobial properties.
Read more →Competitive Position
How TTRX ranks across every disease it competes inCompetitive Position is a premium feature
See how TTRX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial